ARID1A and gastric cancer: Among GC cases having stage I&II disease only 18.6% were having reduced ARID1A mRNA expression compared to 39.4% patients with stage III&IV disease and reduced ARID1A mRNA expression (OR = 2.8; p = 0.03).